Abstract:BACKGROUND:In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterogeneous. A better understanding of the genomic alterations occurring in these tumors could explain the prognostic heterogeneity observed in these patients.METHODS:We retrospectively analyzed 96 patients with NSCLC with ALK detected by immunohistochemical staining (VENTANA anti-ALK(D5F3) Rabbit Monoclonal Primary Antibody). Cancer tissues were subjected to next-generation sequencing using a panel of 520 cancer-related genes. The genomic landscape, distribution of ALK fusion variants, and clinicopathological characteristics of the patients were evaluated. The correlations of genomic alterations with clinical outcomes were also assessed.RESULTS:Among the 96 patients with immunohistochemically identified ALK fusions, 80 (83%) were confirmed by next-generation sequencing. TP53 mutation was the most commonly co-occurring mutation with ALK rearrangement. Concomitant driver mutations [2 Kirsten rat sarcoma viral oncogene homolog (KRAS) G12, 1 epidermal growth factor receptor (EGFR) 19del, and 1 MET exon 14 skipping] were also observed in 4 adenocarcinomas. Echinoderm microtubule associated protein-like 4 (EML4)-ALK fusions were identified in 95% of ALK-rearranged patients, with 16.2% of them also harboring additional non-EML4-ALK fusions. Nineteen non-EML4 translocation partners were also discovered, including 10 novel ones. Survival analyses revealed that patients concurrently harboring PIK3R2 alterations showed a trend toward shorter progression-free survival (6 vs. 13 months, P=0.064) and significantly shorter overall survival (11 vs. 32 months, P=0.004) than did PIK3R2-wild-type patients. Patients with concomitant alterations in PI3K the signaling pathway also had a shorter median overall survival than those without such alterations (23 vs. 32 months, P=0.014), whereas progression-free survival did not differ significantly.CONCLUSIONS:The spectrum of ALK-fusion variants and the landscape of concomitant genomic alterations were delineated in 96 NSCLC patients. Our study also demonstrated the prognostic value of concomitant alterations in crizotinib-treated patients, which could facilitate improved stratification of ALK-rearranged NSCLC patients in the selection of candidates who could optimally benefit from therapy.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

Concomitant Mutation Status of ALK-rearranged Non-Small Cell Lung Cancers and Its Prognostic Impact on Patients Treated with Crizotinib

Characteristics and Response to Crizotinib in Lung Cancer Patients with MET Amplification Detected by Next-Generation Sequencing

Effectiveness of Crizotinib in a Patient with Mesenchymal-Epithelial Transition Overexpression/fluorescence in Situ Hybridization-Negative/next-generation Sequencing-Negative Advanced Lung Adenocarcinoma: a Case Report

A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report

De Novo MET Amplification in Chinese Patients with Non–Small-Cell Lung Cancer and Treatment Efficacy with Crizotinib: A Multicenter Retrospective Study

The Molecular and Immune Characteristics, Antitumor Activity of Crizotinib in Non-Small Cell Lung Cancer (NSCLC) Patients with MET Exon 14 Skipping Alterations.

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

A Pooled Analysis of Clinical Outcome in Driver-Gene Negative Non-Small Cell Lung Cancer Patients with MET Overexpression Treated with Gumarontinib

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Crizotinib in Advanced Non-Small-cell Lung Cancer with Concomitant ALK Rearrangement and C-Met Overexpression

Lung Adenocarcinoma Harboring Concomitant SPTBN1-AL K Fusion, C-Met Overexpression, and HER-2 Amplification with Inherent Resistance to Crizotinib, Chemotherapy, and Radiotherapy

The Characteristics of MET Exon 14 Skipping Mutations in Chinese Non-Small Cell Lung Cancer: A Retrospective Analysis.

P-053 MET Overexpression and Amplification Define a Distinct Molecular Subgroup for Targeted Therapies in Gastric Cancer

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping